FIGURE 6.

SIRP-1 and SIRP-2 combine with tumor-opsonizing Abs to potentiate phagocytosis of cancer cell lines. (A) SIRP-1 and (B) SIRP-2 combine with anti–PD-1 mAb avelumab, anti–epidermal growth factor receptor mAb cetuximab, and anti-CD20 mAb rituximab to potentiate human moMΦ phagocytosis of ES-2, DLD-1, and Raji cell lines, respectively. (C) SIRP-1 also combines with anti-CD47 mAb AO-176 to potentiate phagocytosis of Jurkat cells. All panels show mean ± SEM; a representative minimum n = 2 is shown.